HODGKIN LYMPHOMA

Poster number

Title

Submitting author

City and Country

189

AMAHRELIS : Adcetris maintenance after autologous stem cell transplantation in Hodgkin lymphoma : a real life study from SFGMTC and LYSA groups.

Bénédicte Deau

Paris, France

190

Long-term follow-up and biomarker analyses of brentuximab vedotin and DHAP in relapsed/refractory Hodgkin lymphoma patients: the HOVON/LLPC Transplant Brave study.

Julia Driessen

Amsterdam, Netherlands

191

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

Alice Morigi

Bologna, Italy

192

Camrelizumab Combined with GEMOX in Patients with Relapsed or Refractory Hodgkin Lymphoma

Yan Xie

Beijing, China

193

Health-Related Quality of Life Among Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in a Phase 3 Study of Pembrolizumab Versus Brentuximab Vedotin

Pier Luigi Zinzani

Bologna, Italy

194

Real world outcomes and responses to second-line therapy in relapsed/refractory Hodgkin lymphoma: a multicentre UK study

Rohan Shotton

Manchester, UK

195

Clinical Outcomes of Relapsed Hodgkin Lymphoma Patients after Contemporary First-Line Treatment: Results from the German Hodgkin Study Group

Paul Bröckelmann

Cologne, Germany

196

PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA LH-05 trial

Astrid Pavlovsky

Buenos Aires, Argentina

197

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA

Anna Santarsieri

Cambridge, UK

198

Mature Results from a Phase II Trial of Brentuximab Vedotin plus Adriamycin and Dacarbazine Without Radiation in Non-bulky Limited Stage Classical Hodgkin Lymphoma

Jeremy Abramson

Boston, MA, USA

199

Brentuximab vedotin as consolidation treatment in patients with stage I/II classical Hodgkin’s lymphoma and a positive FDG-PET after 2 cycles of ABVD: a LYSA phase 2 study.

Thomas Gastinne

Nantes, France

200

Outcomes after initial refusal of curative treatment in patients with Hodgkin lymphoma in British Columbia

Manik Chahal

Vancouver, Canada

201

Prognostic factors in elderly patients with classical Hodgkin Lymphoma - a joint analysis of two clinical databases

Martin Fehr

St. Gallen, Switzerland

202

MTV, TLG and SUV max as promising parameters to predict early response in patients with HL treated with ABVD. A retrospective sub-analysis of the GATLA-LH-05 trial.

Julieta Iorio

Ciudad de Buenos Aires-Recoleta, Argentina

203

Baseline Maximum Tumour Diameter Is Associated with Event-Free Survival for PET-Negative Patients with Limited-Stage Hodgkin Lymphoma: Analysis of the H10 and RAPID Trials

Elizabeth Phillips

Manchester, UK

204

Sarcopenia is an independent prognostic factor in elderly male patients with classical Hodgkin Lymphoma: results from a multicenter experience

Vittorio Zilioli

Milan, Italy

205

Gut microbiota role in response to checkpoint inhibitor treatment in patients with relapsed/refractory B-cell Hodgkin lymphoma: an interim analysis from MICRO-LINF study

Beatrice Casadei

Bologna, Italy

206

Characterization of cancer associated fibroblasts in classical Hodgkin lymphoma

Kristiina Karihtala

Helsinki, Finland

207

Tracking clonal hematopoiesis in patients with classical Hodgkin's lymphoma

Andrea Marra

Perugia, Italy